SOURCE: Decision Diagnostics Corp.

Decision Diagnostics Corp.

March 14, 2016 20:00 ET

DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement

Company's Decision IT and Pharma Tech Solutions Subsidiaries Demand $400 Million in Damages

LOS ANGELES, CA--(Marketwired - Mar 14, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate™ glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure™ glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, Case 2:16-cv-00564, titled Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al which named Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) and alleged infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400 million. 

The news contained in this release covers the companies' U.S. Patent numbers 6,153,069, an apparatus patent, and 6,413,411 method claims. Expanded information related to these actions will be circulated within the next several days.

Forward-Looking Statements:

This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of March 14, 2016, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.

Contact Information